{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:12:38Z","timestamp":1789517558608,"version":"build-2803163510"},"reference-count":33,"publisher":"CSIRO Publishing","issue":"3","funder":[{"DOI":"10.13039\/501100001787","name":"University of South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001787","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence","award":["GNT1196900"],"award-info":[{"award-number":["GNT1196900"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to describe national trends in pancreatic enzyme replacement therapy (PERT) dispensing in Australia and assess changes following the introduction of 60-day prescription dispensing, in the context of medicine shortages and market changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Publicly available Pharmaceutical Benefits Scheme (PBS) data for pancreatic enzyme extract dispensings were analysed from February 2014 to October 2025. Monthly dispensing rates per 100,000 population were calculated using Australian Bureau of Statistics population estimates. Medicine shortage periods, including sustained shortages in 2025, were identified using the Therapeutic Goods Administration (TGA) database. Interrupted time-series analyses were conducted to evaluate changes in dispensing of 5000 U, 10,000 U, 25,000 U, and 35,000 U strengths before (July 2021\u2013August 2023) and after (October 2023\u2013October 2025) implementation of 60-day dispensing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PERT dispensing increased from 33 to 85 dispensings per 100,000 population per month between February 2014 and October 2025 (160% increase). Dispensing patterns varied across formulations in response to market changes. Following the introduction of the 35,000 U strength in July 2021, its share of total dispensings increased, whereas dispensing of the discontinued 40,000 U strength declined from November 2020. Interrupted time-series analyses indicated a statistically significant immediate change in dispensing only for the 5000 U strength of PERT. Statistically significant changes in dispensing were observed following introduction of the policy for the 25,000 and 35,000 strengths, but the absolute difference in dispensings per 100,000 population per month was minimal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PERT use in Australia has increased over time, reflecting growing clinical need. Although medicine shortages influenced utilisation patterns across strengths, the introduction of 60-day dispensing was not associated with significant changes in PBS dispensing of PERT. Ongoing monitoring is warranted given reliance on a single-brand therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/ah26080","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:09:11Z","timestamp":1787015351000},"source":"Crossref","is-referenced-by-count":1,"title":["Extended dispensing intervals for pancreatic enzyme extract without access destabilisation: a national retrospective study evaluating supply resilience during policy changes and medicine shortages in Australia"],"prefix":"10.1071","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4096-5607","authenticated-orcid":true,"given":"Mia","family":"Bonython","sequence":"first","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences A , , , , .","place":["Adelaide, SA, Australia"]},{"name":"College of Health, Adelaide University A , , , , .","place":["Adelaide, SA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5063-6128","authenticated-orcid":true,"given":"Lisa","family":"Kalisch Ellett","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences A , , , , .","place":["Adelaide, SA, Australia"]},{"name":"College of Health, Adelaide University A , , , , .","place":["Adelaide, SA, Australia"]},{"name":"Quality Use of Medicines and Pharmacy Research Centre B , , , , .","place":["Adelaide, SA, Australia"]},{"name":"College of Health, Adelaide University B , , , , .","place":["Adelaide, SA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0171-3972","authenticated-orcid":true,"given":"Kelly","family":"Hall","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences A , , , , .","place":["Adelaide, SA, Australia"]},{"name":"College of Health, Adelaide University A , , , , .","place":["Adelaide, SA, Australia"]},{"name":"Quality Use of Medicines and Pharmacy Research Centre B , , , , .","place":["Adelaide, SA, Australia"]},{"name":"College of Health, Adelaide University B , , , , .","place":["Adelaide, SA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8043-0200","authenticated-orcid":true,"given":"Joanne","family":"Carson","sequence":"additional","affiliation":[{"name":"Medicines Intelligence Research Program, School of Population Health C , , , , .","place":["Sydney, NSW, Australia"]},{"name":"Faculty of Medicine and Health, UNSW Sydney C , , , , .","place":["Sydney, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7137-6855","authenticated-orcid":true,"given":"Sallie-Anne","family":"Pearson","sequence":"additional","affiliation":[{"name":"Medicines Intelligence Research Program, School of Population Health C , , , , .","place":["Sydney, NSW, Australia"]},{"name":"Faculty of Medicine and Health, UNSW Sydney C , , , , .","place":["Sydney, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8730-8910","authenticated-orcid":true,"given":"Nicole","family":"Pratt","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences A , , , , .","place":["Adelaide, SA, Australia"]},{"name":"College of Health, Adelaide University A , , , , .","place":["Adelaide, SA, Australia"]},{"name":"Quality Use of Medicines and Pharmacy Research Centre B , , , , .","place":["Adelaide, SA, Australia"]},{"name":"College of Health, Adelaide University B , , , , .","place":["Adelaide, SA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-3504","authenticated-orcid":true,"given":"Jack","family":"Janetzki","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences A , , , , .","place":["Adelaide, SA, Australia"]},{"name":"College of Health, Adelaide University A , , , , .","place":["Adelaide, SA, Australia"]},{"name":"Quality Use of Medicines and Pharmacy Research Centre B , , , , .","place":["Adelaide, SA, Australia"]},{"name":"College of Health, Adelaide University B , , , , .","place":["Adelaide, SA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"67","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"issue":"8","key":"2026081721090630900_R1","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.pan.2024.10.008","article-title":"Prescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: cross-sectional survey across New Zealand and Australia.","volume":"24","author":"Landers","year":"2024","journal-title":"Pancreatology"},{"key":"2026081721090630900_R2","unstructured":"Australian Medicines Handbook Pty Ltd, Health Communication Network. Australian medicines handbook. Australian Medicines Handbook Pty Ltd; 2025."},{"issue":"34\u201335","key":"2026081721090630900_R3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3238\/arztebl.2011.0578","article-title":"Pancreatic enzyme therapy.","volume":"108","author":"M\u00f6ssner","year":"2010","journal-title":"Dtsch Arztebl Int"},{"issue":"33","key":"2026081721090630900_R4","doi-asserted-by":"publisher","first-page":"11467","DOI":"10.3748\/wjg.v20.i33.11467","article-title":"Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century.","volume":"20","author":"Trang","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"7","key":"2026081721090630900_R5","doi-asserted-by":"publisher","DOI":"10.3390\/nu14071341","article-title":"Pancreatic enzyme replacement therapy in cystic fibrosis.","volume":"14","author":"Freswick","year":"2022","journal-title":"Nutrients"},{"issue":"8","key":"2026081721090630900_R6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008227.pub4","article-title":"Pancreatic enzyme replacement therapy for people with cystic fibrosis.","volume":"8","author":"Somaraju","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2026081721090630900_R7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24374-4","article-title":"Survival of people with cystic fibrosis in Australia.","volume":"12","author":"Ruseckaite","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"2026081721090630900_R8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5694\/mja2.51797","article-title":"Diagnosis of cystic fibrosis in adults: Australian Cystic Fibrosis Data Registry data, 2000\u20132019.","volume":"218","author":"Lin","year":"2023","journal-title":"Med J Aust"},{"key":"2026081721090630900_R9"},{"key":"2026081721090630900_R10"},{"key":"2026081721090630900_R11"},{"issue":"Suppl 1","key":"2026081721090630900_R12","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0001117472.84114.43","article-title":"Evaluating the uptake and potential cost savings of a new 60-day dispensing policy for antihypertensive medicines in Australia.","volume":"43","author":"Wang","year":"2025","journal-title":"J Hypertens"},{"key":"2026081721090630900_R13"},{"key":"2026081721090630900_R14"},{"key":"2026081721090630900_R15"},{"key":"2026081721090630900_R16","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8","article-title":"The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers.","volume":"8","author":"Mellish","year":"2015","journal-title":"BMC Res Notes"},{"key":"2026081721090630900_R17"},{"key":"2026081721090630900_R18"},{"key":"2026081721090630900_R19"},{"issue":"3","key":"2026081721090630900_R20","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5776","article-title":"Medicine utilization studies in Australian individual-level dispensing data: a blinded, multi-center replicated analysis.","volume":"33","author":"Gillies","year":"2024","journal-title":"Pharmacoepidemiology and Drug"},{"key":"2026081721090630900_R21"},{"issue":"4","key":"2026081721090630900_R22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research.","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"2026081721090630900_R23","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.acap.2013.08.002","article-title":"Use of interrupted time series analysis in evaluating health care quality improvements.","volume":"13","author":"Penfold","year":"2013","journal-title":"Acad Pediatr"},{"issue":"6","key":"2026081721090630900_R24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.12788\/jhm.3543","article-title":"Methodological progress note: interrupted time series.","volume":"16","author":"Mahant","year":"2021","journal-title":"J Hosp Med"},{"issue":"8","key":"2026081721090630900_R25","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jclinepi.2014.12.018","article-title":"Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations.","volume":"68","author":"Jandoc","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2026081721090630900_R26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/bmjqs-2021-013910","article-title":"Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis.","volume":"31","author":"Morrow","year":"2022","journal-title":"BMJ Qual Saf"},{"issue":"1","key":"2026081721090630900_R27","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01235-8","article-title":"Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions.","volume":"21","author":"Schaffer","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"669","key":"2026081721090630900_R28","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.3399\/bjgp18X695501","article-title":"Impact of issuing longer- versus shorter-duration prescriptions: a systematic review.","volume":"68","author":"King","year":"2018","journal-title":"Br J Gen Pract"},{"issue":"3","key":"2026081721090630900_R29","doi-asserted-by":"publisher","DOI":"10.5600\/mmrr.002.03.a04","article-title":"Medication days\u2019 supply, adherence, wastage, and cost among chronic patients in Medicaid.","volume":"2","author":"Taitel","year":"2012","journal-title":"Medicare Medicaid Res Rev"},{"key":"2026081721090630900_R30"},{"key":"2026081721090630900_R31"},{"key":"2026081721090630900_R32","article-title":"Taking its toll: the global pancreatic enzyme shortage.","author":"Lipanovic","year":"2024","journal-title":"Pharm J"},{"key":"2026081721090630900_R33"}],"container-title":["Australian Health Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/ah\/article-pdf\/doi\/10.1071\/AH26080\/1949346\/ah26080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/ah\/article-pdf\/doi\/10.1071\/AH26080\/1949346\/ah26080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:09:13Z","timestamp":1787015353000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/ah\/article\/50\/3\/AH26080\/275603\/Extended-dispensing-intervals-for-pancreatic"}},"subtitle":[],"editor":[{"given":"Robert","family":"Borotkanics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1071\/ah26080","relation":{},"ISSN":["0156-5788","1449-8944"],"issn-type":[{"value":"0156-5788","type":"print"},{"value":"1449-8944","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"AH26080"}}